Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.90
+0.12 (+0.42%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024
From
Pfizer Inc.
Via
Business Wire
These 3 Stocks Pay You More Than 5% to Own Them
August 22, 2024
High dividend yields paired with fundamentally sound and undervalued stocks provide opportunities for both income and long-term capital appreciation.
Via
MarketBeat
Mr. Darren Walker, Dr. Albert Bourla, and Secretary General Jens Stoltenberg to be awarded Concordia Leadership Award at the 2024 Annual Summit this September
August 22, 2024
NEW YORK, N.Y., Aug. 22, 2024 (SEND2PRESS NEWSWIRE) -- The Concordia Leadership Council is proud to announce the recipients of the 2024 Leadership Award: Mr. Darren Walker, President of the Ford...
Via
Send2Press
Value Investing: Unearthing 3 Hidden Gems in Today's Market
August 21, 2024
Discover undervalued companies and build long-term wealth through the insightful strategy of value investing.
Via
MarketBeat
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
August 16, 2024
From
Pfizer Inc.
Via
Business Wire
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Via
MarketBeat
Exposures
COVID-19
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
August 12, 2024
From
Pfizer Inc.
Via
Business Wire
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
August 09, 2024
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Phio Pharmaceuticals Announces New Chief Financial Officer
August 01, 2024
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via
Newsfile
Topics
Initial Public Offering
Exposures
Securities Market
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
July 30, 2024
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.
Via
MarketBeat
Topics
ETFs
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
From
Pfizer Inc.
Via
Business Wire
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
July 25, 2024
From
Pfizer Inc.
Via
Business Wire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Pfizer Inc.
Via
Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
July 11, 2024
From
Pfizer Inc.
Via
Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
July 09, 2024
Via
Investor Brand Network
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
July 09, 2024
From
Pfizer Inc.
Via
Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
July 09, 2024
Via
AB Newswire
Exposures
COVID-19
Product Safety
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
3 Stock Giants Analysts Are Bullish On Despite Struggles
July 05, 2024
Despite recent struggles, PYPL, BABA, and PFE present attractive opportunities with favorable P/Es, high dividend yields, and analyst-predicted upsides.
Via
MarketBeat
AbbVie Stock: A Perfect Dip for Investors to Buy
July 03, 2024
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
Via
MarketBeat
Topics
ETFs
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.